Lv11
34 积分 2021-02-13 加入
A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
6小时前
待确认
Exploring new frontiers in LAG-3 biology and therapeutics
2天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
20天前
已完结
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach
21天前
已完结
An introduction to quantitative systems pharmacology for chemical engineers
25天前
已完结
Optimizing Clinical Translation of Bispecific T‐cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
3个月前
已完结
Defining immune reset: achieving sustained remission in autoimmune diseases
3个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
3个月前
已完结
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB
3个月前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
3个月前
已完结
皖公网安备34019202002308
